The cells of a rare, deadly cancer are resistant to immunotherapy. Now researchers may have found the cause, paving the way for a new type of treatment.
Jun 20, 2024
0
15
Investigators from Northwestern University Feinberg School of Medicine and The University of Texas MD Anderson Cancer Center have discovered that using a novel drug to target the STING pathway in glioblastoma reprogrammed ...
Jun 18, 2024
0
6
Glioblastoma multiforme (GBM) is among the most aggressive forms of brain tumors, with few effective treatment options and a bleak prognosis. The current standard of care (SOC), known as the STUPP regimen, includes surgical ...
Jun 12, 2024
0
0
In a major advance for the treatment of the deadly brain cancer glioblastoma, Northwestern Medicine scientists have used ultrasound technology to penetrate the blood-brain barrier and provide a small dose of a chemotherapy ...
Jun 6, 2024
0
82
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median ...
Jun 5, 2024
0
0
Glioblastoma is an aggressive brain cancer that has no cure. A recent chart study of patients with glioblastoma found that taking chemotherapy in the morning was associated with a three- to six-month increase in median survival.
May 20, 2024
0
45
For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is a big problem.
May 20, 2024
0
22
A study appearing in Cancer Cell uncovers the evolutionary dynamics of glioblastoma recurrence through proteogenomic analysis, offering potential therapeutic avenues.
May 10, 2024
0
38
Glioblastoma is an often fatal form of brain cancer, with only 5% of patients surviving beyond five years. The cancer is difficult to treat and almost always becomes resistant to treatment. As a result, recurrence of glioblastoma ...
May 6, 2024
0
1
The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma—a serious and often fatal brain cancer—suppresses the immune system so that the tumor can grow ...
May 3, 2024
0
50
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.
Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.
With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.
This text uses material from Wikipedia licensed under CC BY-SA
